Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 9, 2020
Daily News
January 9, 2020
- Japanese Pharma CEOs Gearing Up for New Endeavors in 2020, Fret Scope of Off-Year Re-Pricing
January 9, 2020
- Keytruda Top New Sales Generator in 2020, Enhertu Seen as Biggest Arrival: Evaluate
January 9, 2020
- Kyowa Kirin Seeks Add’l Indication for Lumicef
January 9, 2020
- Mitsubishi Chemical to Purchase 197 Million Shares of Mitsubishi Tanabe, Taking Over 90% Ownership
January 9, 2020
- ASKA Grabs Japan, South Korea Rights to Insud’s Oral Contraceptive
January 9, 2020
- Promethera Kicks Off PIIb Study of Cell-Based Therapy HepaStem for ACLF in Europe
January 9, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…